Physician profile
James R Conner
NPI 1386619807
$12,309.76
in general payments reported to CMS, 2019-2025
45 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,029 · 2020: $1,910 · 2021: $2,028 · 2022: $1,742 · 2023: $1,713 · 2024: $1,809 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,600.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,067.09 | 2019-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $986.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $965.09 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $958.96 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $869.59 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $862.85 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $672.22 | 2019-2024 | |
| Lilly USA, LLC | $659.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $635.86 | 2019-2024 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $521.07 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $451.80 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Gilead Sciences, INC. | $423.40 | 2019-2025 | |
| Amarin Pharma, INC. | $414.48 | 2019-2022 | |
| Intuitive Surgical, INC. | $404.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.70 | 2019-2023 | Jardiance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.